Anti-angiogenesis and diffuse large B-cell lymphoma: A new treatment opportunity?

Leukemia and Lymphoma

Volumn 47, Issue 6, 2006, Pages 961-962

  Portlock, C ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; BEVACIZUMAB; CYCLOPHOSPHAMIDE; DOXORUBICIN; LACTATE DEHYDROGENASE; PREDNISONE; RITUXIMAB; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR; VINCRISTINE;

ARTERY THROMBOSIS; B CELL LYMPHOMA; CANCER COMBINATION CHEMOTHERAPY; CANCER REGRESSION; CANCER SURVIVAL; CLINICAL TRIAL; COLORECTAL CANCER; CORRELATION ANALYSIS; DIGESTIVE SYSTEM PERFORATION; DISEASE FREE SURVIVAL; DRUG APPROVAL; DRUG SAFETY; FOLLOW UP; FOOD AND DRUG ADMINISTRATION; HUMAN; HYPERTENSION; METASTASIS POTENTIAL; NOTE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RISK ASSESSMENT; TREATMENT OUTCOME; TUMOR VASCULARIZATION; UNSPECIFIED SIDE EFFECT; VEIN THROMBOSIS; WOUND HEALING IMPAIRMENT;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; CYTOKINES; DOXORUBICIN; HUMANS; LYMPHOMA, B-CELL; LYMPHOMA, LARGE-CELL, DIFFUSE; PREDNISONE; PROGNOSIS; RISK; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VINCRISTINE;

EID: 33746308672     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428190600593125     Document Type: Note

References (5)

1. Sehn, L and Chhanabhai, M and Fitzgerald, C and Giu, K and Hoskins, P and Klasa, R and et al. (2005) Revised International Prognostic Index (R-IPI) is a better predictor of outcome than the Standard IPI for patients with diffuse large B-cell lymphoma (DLBCL) treated with rituximab and CHOP (R-CHOP) [abstract] Blood, 106, pp. 492.
2. Ganjoo, K and An, C and Robertson, M and Gordon, L and Sen, J and Weisenbach, J and et al. (2006) Rituximab, Bevacizumab and CHOP (RA-CHOP) in untreated diffuse large B-cell lymphoma: Safety, biomarker and pharmacokinetic analysis Leuk Lymphoma, 47, pp. 998-1005.
3. Midgley, R and Kerr, D. (2005) Bevacizumab - current status and future directions Ann Oncol, 16, pp. 999-1004.
4. Salmon, J and Lockhart, A and Berlin, J. (2005) Anti-angiogenic treatment of gastrointestinal malignancies Cancer Invest, 23, pp. 712-726.
5. Cheson, B and Horning, S and Coiffier, B and Shipp, M and Fisher, R and Connors, J and et al. (1999) Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas J Clin Oncol, 17, pp. 1244-1253.